Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 0.46 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.35 |
| ▸ | HTR1A | P08908 | 2/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20135301 | 0.98 | HTR2C (0.47) | HTR2CKCNA3SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL29688593 | 0.98 | HTR2C (0.47) | HTR2CKCNA3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL29688968 | 0.76 | HTR2C (0.46) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL20809452 | 0.76 | HTR2C (0.46) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL4503187 | 0.76 | HTR2C (0.46) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL20809221 | 0.75 | HTR2C (0.49) | HTR2CSLC6A2SLC6A4HTR1AGABRA1 | |
| Hydrochloric Acid SCHEMBL20135264 | 0.75 | HTR2C (0.47) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| Hydrochloric Acid SCHEMBL8916365 | 0.75 | HTR2C (0.47) | HTR2CSLC6A2SLC6A4SLC6A3HTR1A | |
| Hydrochloric Acid SCHEMBL20135274 | 0.74 | HTR2C (0.50) | HTR2CSLC6A2SLC6A4HTR1AGABRA1 | |
| Hydrochloric Acid SCHEMBL29688677 | 0.74 | HTR2C (0.50) | HTR2CSLC6A2SLC6A4HTR1AGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP1 | HTR2C 3534/4885KCNA3 4493/4885SLC6A2 4833/4885 |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MMP9, MMP2, MMP1 | HTR2C 3675/4885KCNA3 4372/4885SLC6A2 4812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.